Drug Profile
Research programme: CNS disorders therapeutics - Curia/Bristol-Myers Squibb
Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator Albany Molecular Research Inc
- Developer AMRI; Bristol-Myers Squibb
- Class
- Mechanism of Action Biogenic amine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 07 Nov 2013 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
- 27 May 2009 AMRI and Bristol-Myers Squibb continue to evaluate additional compounds in their ongoing research collaboration for CNS disorders
- 27 May 2009 Bristol-Myers Squibb files a CTA with the MPA in Sweden to initiate phase I trials with a second biogenic amine reuptake inhibitor for CNS disorders